PRISM Stock IndexesCurrent Value% Change (Daily)% Change (Inception)Most ActiveTop % GainersTop % Losers
Cannabis$70.50-6.5%-29.5%TLRY 25,764TCNNF 1.297%CRON -13.687%
EV$70.60-6%-29.4%GOEV 12,174SPAQ 5.556%WKHS -24.161%
Gene Therapy$63.70-2.5%-36.3%BLUE 7,817ATRA 29.201%FIXX -16.667%
MedDevices$191.30-3.9%91.3%ATRS 5,230SWAV 17.063%CRMD -57.447%
MedDiagnostics$110.80-6.9%10.8%TTOO 10,426CSTL 7.584%QTRX -54.76%
Solar$109.700.9%9.7%HYSR 7,525SUNW 9.609%SOL -5.394%
Uranium$93.10-2.8%-6.9%UEC 12,228BKUCF 0.489%DNN -4.839%
Vaccines & Cell Therapy$232.90-3.8%132.9%SIGA 16,599GMDA 13.364%NVAX -29.642%
Web 3.0$58.60-4.8%-41.4%MARA 18,162FTFT 5.464%PBTS -10.563%

HONG KONG (Reuters) – Lenovo Group (OTC:LNVGY), the world’s biggest maker of personal computers, reported flat revenue for the April-June quarter when many Chinese cities…
[Read More]

Prism Daily

Atara Biotherapeutics (ATRA) Jumps Up Almost 30% As They Announce Strategy Update

Atara Biotherapeutics (ATRA) shot up almost 30% today as they announced their Q2 update and restructuring plans. ATRA will be reducing cash burn by laying off 20% of their staff, providing a significant boost to their cash runway, which will…

Canopy Growth Corporation Rebounds 21% After Posting Revenue Loss Last Week

Canopy Growth Corporation (CGC) jumped 21% for the day, which is great news for CGC as shares tumbled on Friday. Last week, on Friday, CGC released their Q1 fiscal year results, which showed that the Company's net revenue dropped 19%,…

SIGA Technologies Continues to Rise as Biden Administration Calls Monkeypox a Public Health Emergency

SIGA Technologies (SIGA) jumped almost 20% today as the White House declares monkeypox a public health emergency. Currently, SIGA makes the only medication that is allowed by the FDA to treat monkeypox, a viral disease characterized by fever symptoms as…


CEO3in60 Logo

Learn About Tomorrow’s Leading Companies Straight From The Source

The modern investor needs trusted, relevant information, delivered quickly and concisely. CEO3in60 provides a platform for management to succinctly share their company’s value proposition in their own words. We take the CEOs of the most dynamic up and coming companies and put them in front of the camera to provide you with the top three reasons why you should be paying attention to their business, all in less than sixty seconds.

Asensus Surgical

Asensus Surgical (NYSE American: ASXC) is leading the digital surgical market with Performance-Guided Surgery™, which enhances the work of surgeons using state-of-the-art robotics, augmented intelligence and machine learning. Shameze Rampertab, Chief Financial Officer at Asensus, outlines three value drivers for investors that will have the market paying attention in the coming months.


Soligenix (NASDAQ: SNGX) is developing and commercializing products to treat rare diseases in oncology and dermatology where there is an unmet medical need. Chris Schaber, President and CEO of Soligenix, Inc. spends one minute outlining three value drivers that will have investors

Read more about Soligenix, Inc.

This Week's Feature

Virios Therapeutics (Nasdaq: VIRI) Advancing Potential Paradigm Shift in Fibromyalgia Treatment

Greg Duncan, CEO, Virios Therapeutics
Greg Duncan, CEO, Virios Therapeutics

Armed with near-term catalyst, VIRI is poised for next growth stage

Development-stage biotechnology company Virios Therapeutics (NASDAQ:”VIRI”) is working to advance a new therapeutic approach, one that is focused on addressing a potential root cause of Fibromyalgia (FM), a catalyst the company believes is related to activation of previously dormant herpes virus infection.  VIRI is anticipating top line results this September from its ongoing FM Phase 2b trial, featuring its lead combination antiviral development candidate, oral IMC-1.   An earlier FM Phase 2a study demonstrated IMC-1’s effectiveness and tolerability better than placebo, which could serve as a distinguishing differentiating feature of IMC-1 versus other approved FM treatments.

FM is a medical condition experienced by approximately 2% of the population and is characterized by severe, widespread pain and fatigue, as well as symptoms pertaining to impaired mental health, such as anxiety and depression. Unfortunately, many patients suffering from FM are dissatisfied with available FM treatments.  This dissatisfaction relates to both the limited FDA approved treatment options, all of which are focused solely on symptom management, and the burdensome side-effects often resulting in discontinuation of these approved therapies.

We sat down with Virios CEO Greg Duncan to find out more about the company’s research programs, target diseases and upcoming milestones.


Traders Lens

Gold futures are setting up for a possible inverse head and shoulders

Gold futures are setting up for a possible inverse head and shoulders – we are approaching the neckline here.  If we break it, a move into the high 1,800’s is likely.   Very interesting inflection point – given the backdrop of fed moves and inflation expectations, etc.

[More Traders Lens]

Prism View

Quoin Pharmaceuticals: Clear Clinical Path Forward for Lead Product Candidate in Europe

Following the receipt of Scientific Advice from the European Medicines Agency (EMA), specialty pharmaceutical company, Quoin Pharmaceuticals (Nasdaq: QNRX), has a clear path forward for the clinical development of its lead product candidate for the European market. The EMA truncated…

Soligenix Shares Surge 25% as JAMA Dermatology Publishes Phase 3 Study Findings

After publishing the results of a recent study evaluating its HyBryte™ treatment for early-stage cutaneous T-cell lymphoma, Soligenix, Inc. (Nasdaq: SNGX) saw its shares jump an impressive 25%. The results of the Phase 3 FLASH study, published in peer-reviewed JAMA…

Virios’ Promising Fibromyalgia Treatment Candidate Expects September 2022 Phase 2b Results

With the aim of improving the standard of care for the 10 million Americans living with fibromyalgia (“FM”), Virios Therapeutics (Nasdaq: VIRI) anticipates Phase 2b results for its lead treatment candidate, oral IMC-1, in September. FM is a debilitating, chronic…

ProMIS Neurosciences Soars on First Nasdaq Trading Day

Newly uplisted biotech, ProMIS Neurosciences (Nasdaq: PMN)(TSX: PMN), soared on its first day of trading on…

Quoin (NASDAQ:QNRX) Shares on the Move as Company Announces First Clinical Site Open to Evaluate Netherton Syndrome Treatment

In a significant step forward for rare disease treatment, Quoin Pharmaceuticals announced the opening of the…

Oxford BioDynamics: A Winning Trifecta of Technology, Story and Strong Management

Biotechnology company, Oxford BioDynamics (AIM:OBD), is poised for successful commercialization of its precision medicine tests for…

The Ascension of Asensus in Performance-Guided Surgery

Key commercial and regulatory milestones expected during the second half of 2022 In a recent interview,…